Dr Mark Mason discusses the various trials. In EXPORT AMI trial, the use of Export aspiration device appears safe in patients with AMI.
The routine use of Export device appears associated with improvements in surrogates of microvascular reperfusion but there is no difference in MACCE at 30 days.
In HORIZONS AMI trial, which compared Bivalirudin with UFH + GP IIb/IIIa, there was a lower mortality with bivalirudin at 30 days but with a significantly higher incidence of acute stent thrombosis.
He also discusses AMIHOT I and AMIHOT II trials.